BR112013025866A2 - formulações com viscosidade reduzida - Google Patents

formulações com viscosidade reduzida

Info

Publication number
BR112013025866A2
BR112013025866A2 BR112013025866A BR112013025866A BR112013025866A2 BR 112013025866 A2 BR112013025866 A2 BR 112013025866A2 BR 112013025866 A BR112013025866 A BR 112013025866A BR 112013025866 A BR112013025866 A BR 112013025866A BR 112013025866 A2 BR112013025866 A2 BR 112013025866A2
Authority
BR
Brazil
Prior art keywords
low viscosity
viscosity formulations
formulations
low
avaible
Prior art date
Application number
BR112013025866A
Other languages
English (en)
Portuguese (pt)
Inventor
Kai Zhang
Man Yi Wong
Myrna A Monck
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of BR112013025866A2 publication Critical patent/BR112013025866A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112013025866A 2011-04-07 2012-04-06 formulações com viscosidade reduzida BR112013025866A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161473121P 2011-04-07 2011-04-07
PCT/US2012/032462 WO2012138958A1 (en) 2011-04-07 2012-04-06 Formulations with reduced viscosity

Publications (1)

Publication Number Publication Date
BR112013025866A2 true BR112013025866A2 (pt) 2016-12-20

Family

ID=46969561

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013025866A BR112013025866A2 (pt) 2011-04-07 2012-04-06 formulações com viscosidade reduzida

Country Status (12)

Country Link
US (1) US20140023655A1 (enExample)
EP (2) EP3058952A1 (enExample)
JP (1) JP2014516924A (enExample)
KR (1) KR20140018966A (enExample)
CN (1) CN103596585A (enExample)
AU (2) AU2012240050B2 (enExample)
BR (1) BR112013025866A2 (enExample)
CA (1) CA2832556A1 (enExample)
EA (1) EA201391488A1 (enExample)
IL (1) IL228591A0 (enExample)
SG (1) SG193963A1 (enExample)
WO (1) WO2012138958A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2523688B1 (en) * 2010-01-15 2017-10-11 Kirin-Amgen, Inc. Antibody formulation and therapeutic regimens
CA2853823C (en) * 2011-10-28 2016-12-20 Integritybio Inc. Protein formulations containing amino acids
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
WO2014141149A1 (en) * 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
WO2014169153A1 (en) * 2013-04-10 2014-10-16 Echogen, Inc. Peptide complexes and therapeutic uses
JP6179939B2 (ja) * 2013-07-09 2017-08-16 国立大学法人 筑波大学 高濃度γグロブリン製剤の粘度低下方法
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
CA2962768C (en) 2014-10-01 2023-10-10 Alyssa M. Larson Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
EP3256147B8 (en) * 2015-01-18 2020-10-21 Gloriana Therapeutics, Inc. Therapeutic protein formulations
CN116327923A (zh) 2015-08-24 2023-06-27 葛兰素史密斯克莱知识产权（第2 号）有限公司 生物医药组合物
US11603407B2 (en) * 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
AU2020251627A1 (en) 2019-03-29 2021-11-11 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing antibody against IL-5 and use thereof
JP2023533704A (ja) * 2020-07-13 2023-08-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 高濃度タンパク質製剤用の粘度低減賦形剤及びそれらの組み合わせ

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5747447A (en) * 1992-04-30 1998-05-05 Cor Therapeutics Stable polypeptide composition
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
ES2332402T5 (es) * 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
EP2281837B1 (en) 2001-08-10 2016-10-05 Aberdeen University Antigen binding domains from fish
WO2004039399A1 (en) * 2002-11-01 2004-05-13 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2004060343A1 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Antibody-containing particles and compositions
HRP20050934B1 (hr) * 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
WO2007076062A2 (en) * 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
US9084777B2 (en) * 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
EP2129401B8 (en) * 2006-12-21 2020-01-15 Amgen Inc. Stable buffered formulations containing polypeptides
ES2750254T3 (es) * 2007-09-27 2020-03-25 Amgen Inc Formulaciones farmacéuticas
EP2615115A3 (en) * 2007-11-30 2014-01-08 Glaxo Group Limited Antigen-binding constructs
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
EP2523688B1 (en) * 2010-01-15 2017-10-11 Kirin-Amgen, Inc. Antibody formulation and therapeutic regimens
DK2531218T3 (en) * 2010-02-04 2019-04-01 Csl Behring Ag immunoglobulin
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US20140044727A1 (en) * 2011-04-07 2014-02-13 Glaxosmithkline Llc Formulations with reduced viscosity

Also Published As

Publication number Publication date
EA201391488A1 (ru) 2014-01-30
JP2014516924A (ja) 2014-07-17
AU2016202355A1 (en) 2016-05-05
AU2012240050B2 (en) 2016-01-21
US20140023655A1 (en) 2014-01-23
SG193963A1 (en) 2013-11-29
EP3058952A1 (en) 2016-08-24
EP2694100A4 (en) 2014-10-01
EP2694100A1 (en) 2014-02-12
WO2012138958A1 (en) 2012-10-11
KR20140018966A (ko) 2014-02-13
CA2832556A1 (en) 2012-10-11
IL228591A0 (en) 2013-12-31
AU2012240050A1 (en) 2013-10-17
CN103596585A (zh) 2014-02-19

Similar Documents

Publication Publication Date Title
BR112013025866A2 (pt) formulações com viscosidade reduzida
BR112013028235A2 (pt) refrigerador
BR112013024248A2 (pt) medidor de semente
BR112014001219A2 (pt) perfume
BR112013028251A2 (pt) polipeptídeo
BR112013028512A2 (pt) cápsula
BR112013025845A2 (pt) formulações com viscosidade reduzida
EP3488847C0 (en) SEMIFLUORINATED ALKANE COMPOSITIONS
UY34550A (es) Bencilpirazoles sustituidos
UY34654A (es) Inhibidores de la beta-secretasa
UY34817A (es) Tienopirimidinas
UY33930A (es) Inhibidores novedosos de quinasas
BR112014002403A2 (pt) composição dentifrícia não aquosa
UY4281Q (es) Juguera
BR112014003027A2 (pt) formulação herbicida melhorada
BR112013028039A2 (pt) composição de cimento
BR112014026634A2 (pt) direcionador
BR112013026462A2 (pt) protetor de pé
BR112013032555A2 (pt) composição selante híbrida
UY4181Q (es) Taza
BR112013032536A2 (pt) módulo de conexão elétrica
BR112015001072A2 (pt) misturas refrigerantes
BR112013027221A2 (pt) composição vaginal com base alquil poliglicosídeos
BR112013025764A2 (pt) dispositivo impulsionador
BR112013029778A2 (pt) composição farmacêutica que compreende fexofenadina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]